Amgad Alonazy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amgad Alonazy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Abdulaziz Boqaeid
Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
1 shared publication- Abdulelah Almutairdi
Department of Internal Medicine, Division of Gastroenterology and Hepatology, King Faisal Specialist Hospital, Riyadh 11564, Saudi Arabia
1 shared publication - Abdullah Al-Roqy
Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
1 shared publication Abdullah Alsaeedi
Department of Medicine, Al-Jahra Hospital, Kuwait
1 shared publication- Al-Zahraa Almahlawi
Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
1 shared publication - Asma Sallam
Department of Internal Medicine, King Faisal Specialist Hospital, Riyadh 11564, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
Prevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.
Open AccessPrevalence and Impact of Zinc Deficiency on Clinical Outcomes in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) can lead to zinc deficiency, which plays a critical role in immune function and tissue repair. This study aims to determine the prevalence, clinical characteristics, and impact of zinc deficiency in IBD patients. Methods: This is a retrospective study of patients aged ≥14 years with confirmed IBD and available zinc level measurement. Zinc deficiency was defined as a level p < 0.001) levels, and were more likely to be on corticosteroids (p = 0.04). Zinc deficiency was associated with higher rates of IBD-related hospitalizations (48.0% vs. 17.7%), surgeries (19.6% vs. 5.8%), complications (30.4% vs. 12.4%), and emergency room visits (40.2% vs. 17.3%) (all p < 0.001). Upon multivariate analysis, predictors of IBD-related hospitalization were zinc deficiency (OR 2.42, 95% CI 1.07–5.48, p = 0.03) and low albumin (OR 9.03, 95% CI 3.38–24.15, p < 0.001). Zinc deficiency was associated with IBD-related surgeries (OR 5.23, 95% CI 1.27–21.45, p = 0.02) and complications (OR 3.98, 95% CI 1.52–10.41, p = 0.005). Conclusions: Zinc deficiency is prevalent in patients with IBD, associated with a high inflammatory burden, and was linked to worse clinical outcomes after controlling for markers of inflammation.
- Open Access
- 21 April 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (6) , 1134-1141
The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy
- 21 April 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (6) , 1134-1141
Open AccessThe risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy